Granules India Ltd
Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages.[1]
- Market Cap ₹ 13,930 Cr.
- Current Price ₹ 574
- High / Low ₹ 628 / 412
- Stock P/E 29.2
- Book Value ₹ 153
- Dividend Yield 0.25 %
- ROCE 15.1 %
- ROE 13.9 %
- Face Value ₹ 1.00
Pros
Cons
- The company has delivered a poor sales growth of 11.5% over past five years.
- Company might be capitalizing the interest cost
- Dividend payout has been low at 7.75% of profits over last 3 years
- Promoter holding has decreased over last 3 years: -3.11%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1,084 | 1,292 | 1,357 | 1,411 | 1,685 | 2,279 | 2,599 | 3,238 | 3,765 | 4,512 | 4,506 | 4,482 | 4,512 | |
| 925 | 1,082 | 1,081 | 1,112 | 1,406 | 1,895 | 2,073 | 2,382 | 3,038 | 3,597 | 3,648 | 3,534 | 3,579 | |
| Operating Profit | 159 | 210 | 276 | 299 | 278 | 384 | 526 | 856 | 727 | 915 | 858 | 948 | 933 | 
| OPM % | 15% | 16% | 20% | 21% | 17% | 17% | 20% | 26% | 19% | 20% | 19% | 21% | 21% | 
| 4 | 3 | 5 | 35 | 27 | 75 | 90 | 26 | 13 | 12 | 2 | 41 | 32 | |
| Interest | 20 | 32 | 37 | 32 | 33 | 28 | 27 | 26 | 23 | 56 | 106 | 103 | 100 | 
| Depreciation | 30 | 53 | 58 | 72 | 76 | 105 | 137 | 151 | 159 | 184 | 207 | 226 | 241 | 
| Profit before tax | 112 | 128 | 186 | 230 | 196 | 326 | 451 | 704 | 558 | 687 | 547 | 660 | 623 | 
| Tax % | 33% | 29% | 33% | 28% | 32% | 27% | 26% | 22% | 26% | 25% | 26% | 24% | |
| 75 | 91 | 123 | 165 | 133 | 236 | 335 | 549 | 413 | 517 | 405 | 502 | 480 | |
| EPS in Rs | 3.71 | 4.45 | 5.68 | 7.19 | 5.22 | 9.30 | 13.19 | 22.18 | 16.64 | 21.34 | 16.72 | 20.68 | 19.77 | 
| Dividend Payout % | 9% | 11% | 11% | 13% | 19% | 11% | 8% | 7% | 9% | 7% | 9% | 7% | 
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% | 
| 5 Years: | 12% | 
| 3 Years: | 6% | 
| TTM: | -4% | 
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% | 
| 5 Years: | 9% | 
| 3 Years: | 5% | 
| TTM: | -3% | 
| Stock Price CAGR | |
|---|---|
| 10 Years: | 14% | 
| 5 Years: | 8% | 
| 3 Years: | 15% | 
| 1 Year: | 1% | 
| Return on Equity | |
|---|---|
| 10 Years: | 17% | 
| 5 Years: | 17% | 
| 3 Years: | 15% | 
| Last Year: | 14% | 
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20 | 20 | 22 | 23 | 25 | 25 | 25 | 25 | 25 | 24 | 24 | 24 | 
| Reserves | 336 | 411 | 640 | 881 | 1,279 | 1,504 | 1,818 | 2,149 | 2,562 | 2,811 | 3,201 | 3,691 | 
| 442 | 482 | 641 | 656 | 978 | 991 | 892 | 849 | 1,106 | 1,136 | 1,315 | 1,455 | |
| 194 | 289 | 260 | 319 | 388 | 458 | 487 | 690 | 819 | 932 | 957 | 1,051 | |
| Total Liabilities | 992 | 1,203 | 1,563 | 1,879 | 2,670 | 2,979 | 3,223 | 3,713 | 4,512 | 4,903 | 5,498 | 6,221 | 
| 482 | 617 | 560 | 644 | 777 | 944 | 1,204 | 1,332 | 1,541 | 1,911 | 2,096 | 2,426 | |
| CWIP | 125 | 62 | 77 | 267 | 515 | 496 | 294 | 239 | 356 | 239 | 272 | 440 | 
| Investments | 0 | 0 | 70 | 108 | 157 | 210 | 19 | 19 | 20 | 21 | 22 | 22 | 
| 385 | 524 | 856 | 859 | 1,222 | 1,328 | 1,706 | 2,123 | 2,594 | 2,732 | 3,109 | 3,333 | |
| Total Assets | 992 | 1,203 | 1,563 | 1,879 | 2,670 | 2,979 | 3,223 | 3,713 | 4,512 | 4,903 | 5,498 | 6,221 | 
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 108 | 150 | 151 | 188 | -1 | 262 | 476 | 432 | 332 | 739 | 439 | 867 | |
| -255 | -146 | -162 | -326 | -462 | -270 | -160 | -277 | -379 | -192 | -358 | -689 | |
| 147 | 19 | 86 | 56 | 529 | -17 | -213 | -299 | 190 | -440 | 8 | -93 | |
| Net Cash Flow | 0 | 24 | 75 | -82 | 66 | -25 | 103 | -144 | 143 | 107 | 90 | 85 | 
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 37 | 39 | 101 | 108 | 136 | 108 | 93 | 86 | 90 | 77 | 80 | 77 | 
| Inventory Days | 99 | 110 | 128 | 145 | 114 | 112 | 125 | 205 | 190 | 182 | 235 | 284 | 
| Days Payable | 77 | 92 | 91 | 116 | 112 | 94 | 102 | 142 | 124 | 124 | 135 | 154 | 
| Cash Conversion Cycle | 59 | 57 | 138 | 137 | 138 | 126 | 116 | 150 | 156 | 135 | 179 | 207 | 
| Working Capital Days | 14 | 6 | 9 | -2 | 42 | 48 | 63 | 62 | 44 | 36 | 35 | 42 | 
| ROCE % | 20% | 19% | 20% | 18% | 12% | 15% | 17% | 25% | 17% | 19% | 15% | 15% | 
Documents
Announcements
- 
        
          Board Meeting Intimation for Inter-Alia, To Consider And Approve The Unaudited Financial Results For The Second Quarter And Half-Year Ended On September 30, 2025.
          
            16h - Board meeting 13 Nov 2025 to approve Q2/H1 results (ended Sep 30, 2025); insider window closed till Nov 1.
- 
        
          Announcement under Regulation 30 (LODR)-Press Release / Media Release
          
            1d - Oct 29, 2025: Bonthapally API unit received US FDA EIR (VAI) after June 2025 inspection; one observation.
- 
        
          Updates
          
            1d - Customs penalty Rs.43,32,831 plus interest for misclassification of imports (FY2019-20 & FY2020-21); order dated 22.10.2025
- Closure of Trading Window 25 Sep
- 
        
          Announcement under Regulation 30 (LODR)-Allotment
          
            4 Sep - Allotment of 25,000 equity shares under ESOS 2017 on September 4, 2025.
Annual reports
- 
    
      Financial Year 2025
      from bse
- 
    
      Financial Year 2024
      from bse
- 
    
      Financial Year 2023
      from bse
- 
    
      Financial Year 2022
      from bse
- 
    
      Financial Year 2021
      from bse
- 
    
      Financial Year 2020
      from bse
- 
    
      Financial Year 2019
      from bse
- 
    
      Financial Year 2018
      from bse
- 
    
      Financial Year 2017
      from bse
- 
    
      Financial Year 2016
      from bse
- 
    
      Financial Year 2015
      from bse
- 
    
      Financial Year 2014
      from bse
- 
    
      Financial Year 2013
      from bse
- 
    
      Financial Year 2012
      from bse
- 
    
      Financial Year 2011
      from bse
Concalls
- 
      Aug 2025Transcript PPT REC
- 
      Jun 2025Transcript PPT REC
- 
      Jan 2025Transcript PPT
- 
      Nov 2024Transcript PPT
- 
      Aug 2024Transcript PPT
- 
      May 2024Transcript PPT
- 
      Jan 2024Transcript PPT REC
- 
      Nov 2023Transcript PPT
- 
      Aug 2023Transcript PPT
- 
      May 2023Transcript PPT REC
- 
      Jan 2023Transcript PPT
- 
      Oct 2022Transcript PPT
- 
      Aug 2022Transcript PPT
- 
      May 2022Transcript PPT
- 
      Feb 2022Transcript PPT
- 
      Nov 2021Transcript PPT
- 
      Jul 2021Transcript PPT
- 
      Jun 2021TranscriptPPT
- 
      May 2021TranscriptPPT
- 
      May 2021Transcript PPT
- 
      Jan 2021Transcript PPT
- 
      Oct 2020Transcript PPT
- 
      Jul 2020Transcript PPT
- 
      Jun 2020Transcript PPT
- 
      Jan 2020Transcript PPT
- 
      Dec 2019TranscriptNotesPPT
- 
      Oct 2019Transcript PPT
- 
      Jul 2019Transcript PPT
- 
      May 2019Transcript PPT
- 
      Jan 2019Transcript PPT
- 
      Oct 2018Transcript PPT
- 
      Jul 2018TranscriptNotesPPT
- 
      May 2018TranscriptNotesPPT
- 
      Feb 2018TranscriptNotesPPT
- 
      Nov 2017TranscriptNotesPPT
- 
      Aug 2017TranscriptNotesPPT
- 
      May 2017TranscriptNotesPPT
- 
      Jan 2017TranscriptNotesPPT
- 
      Nov 2016TranscriptNotesPPT
- 
      Aug 2016TranscriptNotesPPT
- 
      Apr 2016TranscriptNotesPPT
- 
      Jan 2016TranscriptNotesPPT
Business Segments